Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic stroke. The recent results of the CAPRIE, CURE, and CREDO studies formed the rationale for the MATCH, designed to test whether the association of clopidogrel and aspirin was better than clopidogrel alone for the prevention of vascular events among high-risk ischemic cerebrovascular patients. Although the benefits were outweighed for a higher bleeding risk in the combination group, this study will provide important insight for upcoming trials in other to determine what populations might mostly benefit from these drugs for the secondary prevention of stroke in the future
Abstract Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke b...
The article tells discusses the role of antiplatelet therapy in the prevention of atherothrombotic s...
Several meta-analyses have shown that platelet aggregation inhibitors can make a major contribution ...
Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic stroke. The ...
Aspirin (acetylsalicylic acid) is the most widely studied and prescribed antiplatelet drug for patie...
Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) repres...
Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity...
The prevention of secondary vascular events is of paramount importance in patients with a history of...
Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. Combination th...
New studies have refined the role of antiplatelet therapy in secondary prevention after noncardioemb...
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review ...
The secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy, and the pre...
Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic dis...
Role of antiplatelet therapy in secondary stroke prevention is of major significance. Antiplatelet a...
BackgroundSeveral clinical trials reported that clopidogrel was superior to aspirin in secondary str...
Abstract Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke b...
The article tells discusses the role of antiplatelet therapy in the prevention of atherothrombotic s...
Several meta-analyses have shown that platelet aggregation inhibitors can make a major contribution ...
Antiplatelet drugs have an established efficacy in the secondary prevention of ischemic stroke. The ...
Aspirin (acetylsalicylic acid) is the most widely studied and prescribed antiplatelet drug for patie...
Reduction of hazard risk of cerebral ischemic event (stroke, transient ischemic attack (TIA)) repres...
Antiplatelets represent a diverse group of agents that share the ability to reduce platelet activity...
The prevention of secondary vascular events is of paramount importance in patients with a history of...
Aspirin, dipyridamole and clopidogrel are effective in secondary vascular prevention. Combination th...
New studies have refined the role of antiplatelet therapy in secondary prevention after noncardioemb...
Antiplatelet therapy is one of the mainstays for secondary stroke prevention. This narrative review ...
The secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy, and the pre...
Clopidogrel was superior to aspirin in patients with previous manifestations of atherothrombotic dis...
Role of antiplatelet therapy in secondary stroke prevention is of major significance. Antiplatelet a...
BackgroundSeveral clinical trials reported that clopidogrel was superior to aspirin in secondary str...
Abstract Background Antiplatelet drugs may prevent recurrent ischemic events after ischemic stroke b...
The article tells discusses the role of antiplatelet therapy in the prevention of atherothrombotic s...
Several meta-analyses have shown that platelet aggregation inhibitors can make a major contribution ...